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Impairment of phenylalanine conversion to tyrosine in end-
stage renal disease causing tyrosine deficiency.
Background. Tyrosine is not considered an indispensable
amino acid because in humans phenylalanine is converted to
tyrosine. Recent human studies demonstrated that tyrosine pro-
duction from phenylalanine occurs not only in liver but also in
kidney.
Methods. Here we report results from studies, performed in
end-stage renal disease (ESRD) patients and in healthy controls
using [15N] phenylalanine and [2H4] tyrosine as tracers demon-
strating the mechanism of tyrosine deficiency in patients with
renal failure.
Results. Phenylalanine flux (an index of protein breakdown)
was identical in both groups either before or during an infusion
of amino acid mixture. In contrast, tyrosine flux (representing
protein breakdown and tyrosine appearance from phenylala-
nine) and conversion of phenylalanine to tyrosine were lower in
ESRD patients [2.05 ± 0.30 lmol/kg fat-free mass (FFM)/hour
and 2.59 ± 0.52 lmol/kg FFM/hour, before and during amino
acid infusion, respectively] than in the control subjects (4.07 ±
0.54 lmol/kg FFM/hour and 5.53 ± 0.86 lmol/kg FFM/hour, P <
0.02, ESRD vs. controls, respectively). Plasma tyrosine concen-
trations in ESRD patients remained 40% lower than the con-
trols during the postabsorptive state and following amino acid
replacement.
Conclusion. We conclude that reduced conversion of pheny-
lalanine to tyrosine causes tyrosine deficiency in patients with
ESRD prompting to propose that tyrosine replacement is po-
tentially required in patients with ESRD.
Tyrosine is not considered an essential amino acid in
humans because unlike other essential amino acids such
as branched chain amino acids and phenylalanine, tyro-
sine can be produced in the body by the hydroxylation on
phenylalanine by phenylalanine hydroxylase. Phenylala-
nine hydroxylase was, until recently, thought to be exclu-
sively located in liver in human subjects. Studies based on
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stable isotopes of phenylalanine and tyrosine, and mea-
surements of these amino acids and their isotopic abun-
dance in artery and renal vein clearly demonstrated that
tyrosine is produced in kidney at least as much as in liver
[1, 2]. Moreover, most of the tyrosine in liver is catab-
olized (a common catabolic pathway for phenylalanine
and tyrosine) [1, 2]. Kidneys produce and release tyro-
sine to the systemic circulation, providing the main source
(other than tyrosine appearing from protein breakdown)
of tyrosine in the systemic circulation [1, 2]. Most of the
commercially available amino acid mixtures have only
low concentrations of tyrosine based on an assumption
that normally phenylalanine is converted to tyrosine and
because of the low solubility of tyrosine. It is possible that
phenylalanine is not converted efficiently to tyrosine in
end-stage renal disease (ESRD). The report that kidney
is a key source of circulating tyrosine in healthy people
prompted us to determine whether reduced phenylala-
nine conversion to tyrosine may explain the intriguing
observations of altered phenylalanine and tyrosine levels
in ESRD patients [3–6]. Elevated phenylalanine concen-
trations in the plasma of chronic renal failure patients
have been observed, but it was constantly attributed to
liver dysfunction and generalized phenylalanine hydrox-
ylase activity. We hypothesized that tyrosine may be con-
sidered as an essential amino acid in patients with ESRD
because tyrosine production from phenylalanine is im-
paired in these patients. A reduced supply of an amino
acid in the fasted state may contribute to the muscle wast-
ing in ESRD patients [7]. It is also possible that when
parenteral nutrition—based on commercially available
amino acid mixture—is administered to ESRD patients,
a decreased tyrosine availability could be a limiting fac-
tor for the stimulation of protein synthesis and may con-
tribute to protein wasting.
Therefore, to determine whether phenylalanine con-
version to tyrosine is reduced in ESRD patients, we as-
sessed phenylalanine and tyrosine fluxes, and conversion
rate of phenylalanine to tyrosine in ESRD patients and
in control subjects, matched for age, gender, and body
mass index (BMI). We then assessed the response of
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Table 1. Amino acid composition of aminosyn
Ingredient Concentration
Arginine 980 mg/100 mL
Glycine 1.28 g/100 mL
Histidine 300 mg/100 mL
Isoleucine 720 mg/100 mL
L-Alanine 1.28 g/100 mL
L-Methionine 400 mg/100 mL
Leucine 940 mg/100 mL
Lysine acetate 720 mg/100 mL
Phenylalanine 440 mg/100 mL
Proline 860 mg/100 mL
Serine 420 mg/100 mL
Threonine 520 mg/100 mL
Tryptophan 160 mg/100 mL
Tyrosine 44 mg/100 mL
Valine 800 mg/100 mL
phenylalanine and tyrosine metabolism to an intravenous
infusion of a commonly used amino acid mixture just as
parenteral nutrition is administered.
METHODS
Materials
[15N] Phenylalanine (98 mol% excess) (MPE), and
[2H4] tyrosine (91 MPE) were supplied by Cambridge
Isotope Laboratories (Andover, MA, USA). Isotopic pu-
rity of tracers was checked by gas chromatography-mass
spectrometry (GCMS). Solutions of tracer were prepared
by the pharmacy department and tested for sterility and
pyrogens.
Subjects
Six ESRD patients, aged 37 to 66 years, on regular
maintenance in-center hemodialysis were selected for
the study. They were compared to age, gender, and BMI
matched control subjects. All subjects had end stage re-
nal disease due to hypertensive nephrosclerosis (N =
3), polycystic kidney disease (N = 1), focal segmen-
tal glomerulosclerosis (N = 1), and antibiotic-induced
nephrotoxicity (N = 1). All ESRD patients had been
treated with hemodialysis exclusively for at least 6 months
with Cobe Centry3TM dialysis machines and polysulfone
high-flux reusable dialyzers. Standard measurements of
dialysis adequacy and management of ESRD-associated
anemia are provided. All clinical and anthropometric
characteristics of the subjects are presented in Table 1.
None had any infectious disease or was treated with
glucocorticoids before or during the study period. The
Institutional Review Board of the Mayo Clinic and Foun-
dation approved the experimental protocol, and the pur-
pose of the study was explained to the patients before
they gave their written informed consent.
Protocol design
Prior to the study, protein and energy intakes were as-
sessed by a dietician on a 1-week diet history. All tests
were performed the day following a dialysis session in
the postabsorptive state, implying that the last meal was
taken between 6:30 p.m. and 7:00 p.m. in the evening pre-
ceding the study day. A saline line was inserted in an
antecubital vein opposite to the fistula arm at 8:00 p.m.
Tracers’ infusions began the next day at 3:00 a.m. un-
til 11:00 a.m. A priming dose of [15N] phenylalanine [1
mg/kg fat-free mass (FFM)], [15N] tyrosine (0.3 mg/kg
FFM) and [2H4] tyrosine (0.6 mg/kg FFM) injection was
followed by a continuous infusion of [15N] phenylala-
nine (1 mg/kg FFM/hour) and [2H4] tyrosine (0.6 mg/kg
FFM/hour). At 7:00 a.m. (T240 minutes) tracers’ in-
fusion rates were increased for [15N] phenylalanine at
1.5 mg/kg FFM/hour and [2H4] tyrosine at 0.65 mg/kg
FFM/hour and saline solution was replaced by an amino
acid mixture (aminosyn 10%) (Table 1) (Abbott Labora-
tories, Chicago, IL, USA) which was infused at a rate of
1.6 mL/kg FFM/hour. The phenylalanine and tyrosine in-
fusion by the aminosyn were, respectively, 44 lmol/kg
FFM/hour for phenylalanine and 4 lmol/kg FFM/hour
for tyrosine in the two groups. Blood samples were drawn
at 3:00 a.m. then at 6:45 a.m., 6:50 a.m., 6:55 a.m., 7:00 a.m.,
and at 10:45 a.m., 10:50 a.m., 10:55 a.m., and 11:00 a.m. for
plasma isotopic enrichments of phenylalanine and tyro-
sine, amino acids concentrations, glucose, and hormonal
analysis.
Body composition analysis
Fat mass and FFM were measured using dual x-ray
absorptiometry analysis. In addition, muscle mass was
estimated from appendicular FFM data as previously
described [8]
Analytic methods and kinetics calculations
[15N] phenylalanine, [15N] tyrosine and [2H4] tyrosine
enrichments were measured as previously described [9]
using GCMS after derivatizing them as previously re-
ported [10].
Free amino acid concentrations in plasma were
measured by high-performance liquid chromatography
(HPLC) system as previously described [11]. Plasma in-
sulin and other hormones [glucagon, cortisol, insulin-
like growth factor (IGF), IGF-BP1, and IGF-BP3) were
measured by chemiluminescent sandwich assay (Sanofi
Diagnostics, Chaska, MN, USA). Plasma glucose con-
centrations were measured enzymatically with an auto-
analyzer (Beckman Instruments, Fullerton, CA, USA).
The calculations of phenylalanine and tyrosine flux
were performed based on the equation previously de-
scribed [12].
Phenylalanine flux or Qp (mmol/kg/hour)
= iPh × ([15NPhp/phenylalanineI) − 1)
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Table 2. Anthropometric, clinical, and biologic data of the population
End-stage
Controls renal disease
Age years 53.83 ± 5.16 53.50 ± 4.88
Weight kg 83.17 ± 6.99 79.37 ± 6.77
Body mass index kg/m2 25.93 ± 1.73 26.26 ± 2.14
Fat-free mass kg 59.73 ± 3.43 53.87 ± 3.00
Muscle mass kg 36.67 ± 2.63 30.36 ± 2.02a
Fat mass % 22.14 ± 2.64 24.45 ± 4.21
Duration of hemodialysis years — 4.25 ± 1.49
Glucose mg/dL 98.08 ± 1.55 93.25 ± 4.46
Bicarbonate mEq/L 26.33 ± 0.99 26.00 ± 0.65
Blood urea nitrogen mg/dL 17.33 ± 1.41 33.00 ± 3.92a
Creatinine mg/dL 1.18 ± 0.03 7.52 ± 0.33a
Serum albumin level g/dL 4.5 ± 0.13 3.9 ± 0.13
Length of dialysis session minutes — 240 ± 15
Urea reduction ratio % — 72 ± 2.62
Hemoglobin g/dL 14.6 ± 0.32 11.7 ± 0.43a
Mean ± SD.
aP < 0.05 end stage renal disease vs. control subjects.
in which iPh is the rate of infusion of [15N] phenylala-
nine, 15NPhp is the arterial plasma isotopic enrichment
of [15N] phenylalanine at plateau and phenylalaninei is
the isotopic enrichment of [15N] phenylalanine infused.
Tyrosine flux (Qt) is calculated in a similar way as pheny-
lalanine using [2H4] tyrosine as tracer.
The conversion rate of phenylalanine to tyrosine (QPT)
is calculated as follows:
QPT = QT ×
15NTP × QP
15NPhP × iPh + QP
in which QT and QP represents the fluxes of phenylala-
nine and tyrosine, 15NTP and at 15NPhP represent [15N]
tyrosine and [15N] phenylalanine enrichment in plasma at
plateau, and iPH represents infusion rate (lmol/kg/hour)
of [15N] phenylalanine.
Statistical analysis
All data are presented as means ± SEM. Factorial anal-
ysis of variance (ANOVA) was used to calculate the dif-
ferences in body composition, hormonal concentrations,
plasma amino acids levels, and phenylalanine and tyro-
sine kinetics between the two groups. Paired t tests were
used in each group to compare baseline and the response
to the amino acid mixture infusion. Results are consid-
ered as significant with P < 0.05.
RESULTS
Anthropometric and clinical data
Patients and control subjects were matched for age,
gender and BMI, so that no statistical significant differ-
ence was detected for these parameters between the two
groups (Table 2). However, when muscle mass was esti-
mated from appendicular FFM, it was found to be signif-
icantly lower in the ESRD patients and close to ∼6 kg
Table 3. Baseline and amino acid–induced changes in plasma
hormones
End-stage renal
Controls disease (ESRD)
Saline Amino acid Saline Amino acid
Insulin 5.9 ± 1.4 7.7 ± 1.3 5.9 ± 1.0 10.0 ± 1.8
Glucagon 60.8 ± 6.1 87.2 ± 12.6 114.1 ± 27.7a 181.3 ± 49.2a
Cortisol 18.8 ± 2.2 14.0 ± 2.3 21.9 ± 2.4 16.4 ± 2.0
Growth 0.19 ± 0.11 1.22 ± 0.50 0.75 ± 0.28a 1.23 ± 0.74
hormone
IGF free 0.73 ± 0.20 0.67 ± 0.15 1.29 ± 0.46 1.07 ± 0.30
IGF total 127 ± 12 129 ± 16 153 ± 33 144 ± 29
IGF-BP1 67.4 ± 15.5 48.1 ± 16.7 35.2 ± 5.2a 19.0 ± 7.6
IGF-BP3 2753 ± 157 2757 ± 185 4169 ± 208b 4036 ± 136b
IGF is insulin-like growth factor. Mean ± SEM.
aP < 0.10 ESRD vs. control subjects.
bP < 0.01 ESRD vs. control subjects.
difference was observed (P < 0.05) (Table 2). Blood urea
and creatinine were much higher in the patients than in
the control subjects (P < 0.001) as expected. However, bi-
carbonate concentration was similar in both groups indi-
cating that ESRD patients were not in a state of acidosis.
Patients with the ESRD had adequate dialysis delivery,
anemia therapy, and there was a statistically no signif-
icant differences in albumin levels between the groups.
The ESRD patients have albumin levels within the range
of a healthy population.
Plasma hormonal concentrations
Insulin, cortisol, free- and total IGF-1 were not statis-
tically different between the two groups in the basal state
or during amino acid infusion (Table 3). However, there
was a tendency of a non-statistically significant higher
baseline and amino acid–induced plasma glucagon (P =
0.09), a higher basal growth hormone (P = 0.08), a lower
basal IGF-BP1 (P = 0.08). Finally, IGF-BP3 concentra-
tions were found markedly elevated in the patients both
at baseline and during amino acid infusion in comparison
with the control subjects (P < 0.001).
Plasma amino acids concentration
As depicted in Table 4, different amino acid profiles
were found between ESRD and control groups. Plasma
tyrosine, valine, leucine, and lysine concentrations were
significantly lower in the ESRD patients than in the
matched control subjects (34 ± 12 vs. 58 ± 11 for plasma
tyrosine, ESRD vs. control subjects, P < 0.05). After
amino acid infusion, there was a global increase for all
amino acids, except for glutamate, glutamine, and tyro-
sine concentrations (30 ± 9 vs. 52 ±13 for plasma tyrosine,
ESRD vs. control subjects, P < 0.05). The infused amino
acid mixture is deficient in these three amino acids but
tyrosine was expected to be produced from conversion
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Table 4. Plasma amino acid concentrations during saline and during
amino acid infusion
Saline Amino acid
Controls ESRD Controls ESRD
Glutamic acid 43 ± 11 51 ± 10 44 ± 11 55 ± 16
Serinle 69 ± 16 49 ± 15 147 ± 43a 112 ± 21
Glutamine 465 ± 73 427 ± 137 465 ± 81 406 ± 103
Histidine 56 ± 8 51 ± 15 78 ± 9a 72 ± 17
Glycine 209 ± 65 356 ± 193 674 ± 162a 825 ± 235
Threonine 87 ± 18 80 ± 33 180 ± 53a 174 ± 55
Alanine 237 ± 65 189 ± 52 497 ± 87a 418 ± 79
Arginine 103 ± 30 92 ± 18 252 ± 59a 222 ± 38
Tyrosine 58 ± 11 34 ± 12b 52 ± 13 30 ± 9b
Valine 183 ± 46 104 ± 26b 417 ± 105a 327 ± 54
Methionine 30 ± 8 24 ± 10 95 ± 12a 75 ± 7
Phenylalanine 63 ± 15 53 ± 12 131 ± 29a 126 ± 10
Isoleucine 54 ± 10 41 ± 12 177 ± 31a 162 ± 15
Leucine 116 ± 22 70 ± 21b 289 ± 44a 236 ± 21
Lysine 189 ± 26 133 ± 34b 370 ± 36a 282 ± 49
ESRD is end-stage renal disease. Mean ± SD.
aIndicates that both controls and ESRD increased (P < 0.05) during amino
acid infusion in comparision with saline.
bP < 0.05 ESRD vs. control subjects.
from phenylalanine. Plasma concentrations of glutamine
and glutamate were similar in both control and ESRD pa-
tients, although tyrosine concentrations remained lower
in ESRD patients during both baseline state and during
amino acid infusion.
Phenylalanine and tyrosine fluxes and
phenylalanine conversion to tyrosine
Phenylalanine fluxes during saline and amino acid infu-
sion (Figs. 1 and 2) were similar in ESRD and the control
subjects (see Fig. 1). The amino acid–induced elevation of
phenylalanine flux was mostly explained by the rate of ap-
pearance of phenylalanine from infused amino acids. The
endogenous flux (appearance rate) of phenylalanine was
reduced by amino acid infusion in both ESRD patients
and controls [51 ± 2 vs. 43 ± 3 (P < 0.05) in controls and
49 ± 2 vs. 42 ± 2 (P < 0.05) in ESRD]. Although pheny-
lalanine flux (representing body protein breakdown) was
similar in ESRD and control groups, the ESRD group
had a lower tyrosine flux during both baseline and dur-
ing amino acid infusion (27.8 ± 1.3 lmol/kg FFM/hour−1
and 26.3 ± 1.3 vs. 32.3 ± 1.2 lmol/kg FFM/hour−1 and
31.5 ± 1.5 lmol/kg FFM/hour−1 for ESRD vs. control at
baseline and after amino acid infusion). The conversion
rate of phenylalanine to tyrosine was ∼ twofold higher
in the control subjects (4.07 ± 0.54 lmol/kg FFM/hour
and 5.53 ± 0.86 lmol/kg FFM/hour before and dur-
ing amino acid infusion, respectively) than the ESRD
patients (2.05 ± 0.30 lmol/kg FFM/hour and 2.59 ±
0.52 lmol/kg FFM/hour, P < 0.02, ESRD vs. controls).
After amino acid infusion, there was a significant increase
in phenylalanine conversion rate in the control subjects
(P < 0.055 using two-tailed t test and <0.03 using one-
tailed test). Since the hypothesis was that phenylalanine
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Fig. 1. Comparison of phenylalanine flux, tyrosine flux, and phenylala-
nine conversion to tyrosine (phenylalanine to tyrosine) during saline
infusion and amino acid (AA) infusion. (A) Phenylalanine flux were
not statistical significantly different between control and end-stage re-
nal disease (ESRD) subjects and in both cases increase occurred with
amino acid infusion. (B) Tyrosine flux was lower in ESRD patients than
controls during saline and amino acid infusion. (C) Phenylalanine con-
version to tyrosine was lower in ESRD patients than controls during
saline and during amino acid infusion.
infusion results in increased conversion of phenylalanine
to tyrosine, it was considered to be significant (one-tailed
t test). A similar increase was not found in the ESRD
patients (P = NS).
The ratios of phenylalanine conversion to tyrosine
to phenylalanine flux and concentration and tyro-
sine/phenylalanine were significantly higher during the
baseline and during amino acid infusion in the control
subjects than in ESRD patients.
DISCUSSION
The current study was performed to test a hy-
pothesis that there is an impairment of phenylalanine
conversion to tyrosine, in patients with ESRD. The results
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Fig. 2. Comparison of phenylalanine conversion to tyrosine as a func-
tion of phenylalanine flux and phenylalanine concentration and ty-
rosine/phenylalanine ration in control and end-stage renal disease
(ESRD) subjects. (A) Phenylalanine to tyrosine/phenylalanine flux.
(B) Phenylalanine to tyrosine/phenylalanine concentration. (C) Tyro-
sine/phenylalanine. All these parameters were lower in ESRD patients
than in the control subjects.
demonstrated a substantial reduction in tyrosine produc-
tion from phenylalanine despite a similarity of phenylala-
nine fluxes (representing protein breakdown) between
the ESRD patients and the control subjects. When the
conversion rate of phenylalanine to tyrosine is expressed
as a function of phenylalanine flux or concentration, the
ESRD patients were noted to have substantially lower
ratios at the baseline and during the infusion of amino
acid mixture. These results together support that ESRD
patients are less efficient in hydroxylating phenylalanine
to tyrosine.
Previous reports suggested that uremic patients have
lower tyrosine levels and tyrosine phenylalanine ratio
[3–6]. The demonstration in the current study that the
conversion rate of phenylalanine to tyrosine is approxi-
mately 50% lower among patients with ESRD in com-
parison with healthy control subjects will explain the
underlying mechanism for this reduced tyrosine levels
in ESRD patients. There are three separate sources of ty-
rosine appearance in people—from diet, appearance of
tyrosine from protein breakdown and conversion from
phenylalanine. A similar level of phenylalanine flux in
the fasted state indicates that the endogenous rates of
appearance of amino acids from protein breakdown are
similar in both controls. Therefore the low tyrosine levels
in these patients should have other cause than a reduced
appearance from protein breakdown. The phenylalanine
conversion is the only other source of tyrosine. Previous
studies demonstrated that kidney plays a pivotal role in
maintaining the circulating tyrosine levels in humans [1]
and that kidney contributes at least 50% to whole body
phenylalanine conversion to tyrosine [1]. Even when ex-
ogenous amino acid infusions with high levels of pheny-
lalanine were similar, the conversion of phenylalanine to
tyrosine was increased only in control subjects but not in
patients with ESRD. The reduced phenylalanine conver-
sion to tyrosine is therefore likely the cause of low plasma
concentrations of tyrosine in patients with ESRD, both
at baseline and during infusion of an amino acid mixture.
This observation is consistent with the previous report
that kidney not only converts phenylalanine to tyrosine
like liver, but unlike liver do not catabolize tyrosine [1].
Kidney, therefore, is a net contributor of tyrosine to the
systemic circulation and this contribution of kidney did
not appear to occur in ESRD patients. As a result, the
contribution of tyrosine appearing from the conversion
from phenylalanine is crucial to maintain normal plasma
levels of tyrosine.
Plasma tyrosine concentrations were consistently
lower in the ESRD patients, indicating that a chroni-
cally lower tyrosine production may reduce tyrosine pool.
Hence, exogenous higher tyrosine requirement may be
needed to maintain the proper amino acid compositions.
Indeed, the relevance of this observation must be con-
sidered in the setting of high amino acids requirement
in clinical conditions which are associated with possible
higher tyrosine requirement (such as critical illness. Of
note, tyrosine is the precursor for all catecholamines).
The current data make a strong case for tyrosine replace-
ment in people with ESRD. However, the tyrosine re-
quirement has to be defined based on various levels of
tyrosine needed to maintain normal tyrosine levels in
the ESRD patients. This has been shown for example
in premature children with low phenylalanine hydroxy-
lase action [13] or during sepsis in children where tyrosine
could be considered as an essential amino acid since pro-
duction was not sufficient to cover tyrosine requirement
[14]. Tyrosine’s poor solubility may limit its availability in
the traditional parenteral solutions and the current study
suggests that the ESRD patients may require parenteral
amino acid mixture with higher tyrosine concentration
than people with normal kidney function.
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Another important aspect on our observation is the on-
going losses of amino acids which occur with hemodialysis
[15–19]. This may explain why phenylalanine did not ac-
cumulate as expected by a limited conversion to tyrosine.
Indeed, among predialysis patients, it is quite usual to find
elevated phenylalanine concentrations [6], which is con-
sistent with a reduced conversion of this amino acid to
tyrosine. It remains to be investigated whether many or
any of the symptoms related to chronic renal failure is due
to altered phenylalanine to tyrosine ratio. Phenylalanine
toxicity may exist among patients with advanced chronic
renal failure who have not yet initiated hemodialysis. The
impact of reduced tyrosine levels in ESRD remains to be
defined. Current estimation of amino acid requirements is
based on studies performed in people with normal kidney
function. Tyrosine balance was studied in healthy peo-
ple with various doses of phenylalanine requirement [20].
Such studies can not be translated directly to people with
ESRD to determine the requirement of tyrosine in their
diet. The reduced muscle protein synthesis, especially of
mitochondrial protein and myosin heavy chain in people
with ESRD [7], resulting in muscle wasting and weakness
may result from lack of compliment of all plasma amino
acids in the free amino acid pool. [7]. This possibility is
supported by recent report showing that insulin in com-
bination with amino acids enhance muscle mitochondrial
protein synthesis [21]. The present study raises several
questions. Is tyrosine an essential amino acid in ESRD
patients? Do we have to consider these patients similar
to phenylketonuric patients from a diet end point? Fi-
nally, does renal transplant correct these abnormalities?
CONCLUSION
Phenylalanine conversion to tyrosine is substantially
reduced in patients with ESRD, both in the basal state
and after an amino acid mixture infusion. As a result,
the end stage renal failure patients appear to be defi-
cient of tyrosine during the postabsorptive state and dur-
ing exogenous infusion of commercially available amino
acid solutions. This metabolic impairment is subtle at the
whole body level, but it may be rate limiting for protein
synthesis or other functions in the body when amino acid
requirements increase. In addition, an accumulation of
phenylalanine in predialysis patients may be the conse-
quence of a lower conversion of phenylalanine to tyro-
sine in these patients. Based on the current study, it is
proposed that serious consideration should be given for
tyrosine replacement for patients with end stage renal
failure.
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